Syndax Pharmaceuticals, Inc. (SNDX)
| Market Cap | 1.79B +50.8% |
| Revenue (ttm) | 217.17M +396.7% |
| Net Income | -243.25M |
| EPS | -2.79 |
| Shares Out | 88.61M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 9,098 |
| Open | 20.61 |
| Previous Close | 20.23 |
| Day's Range | 20.45 - 20.62 |
| 52-Week Range | 8.58 - 25.59 |
| Beta | 0.41 |
| Analysts | Strong Buy |
| Price Target | 39.25 (+94.02%) |
| Earnings Date | Apr 30, 2026 |
About SNDX
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination... [Read more]
Financial Performance
In 2025, Syndax Pharmaceuticals's revenue was $172.35 million, an increase of 627.84% compared to the previous year's $23.68 million. Losses were -$285.42 million, -10.46% less than in 2024.
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for SNDX stock is "Strong Buy." The 12-month stock price target is $39.25, which is an increase of 94.02% from the latest price.
News
Syndax price target lowered to $37 from $38 at UBS
UBS lowered the firm’s price target on Syndax (SNDX) to $37 from $38 and keeps a Buy rating on the shares.
Syndax reports 12 Revuforj abstracts accepted for EHA
Syndax (SNDX) Pharmaceuticals highlighted the release of 12 Revuforj abstracts on the European Hematology Association website in advance of the EHA 2026 Congress, taking place June 11-14. “The breadth...
Syndax Highlights 12 Revuforj® (revumenib) Abstracts Accepted for EHA 2026, Advancing Leadership in Menin Inhibition
– Abstracts highlight strong revumenib activity across the acute leukemia treatment continuum and multiple genetic subtypes – – New real-world data show compelling outcomes and favorable tolerability ...
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
NEW YORK, May 06, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on May 1, 202...
Syndax price target raised to $46 from $45 at Stifel
Stifel raised the firm’s price target on Syndax (SNDX) to $46 from $45 and keeps a Buy rating on the shares. Despite modest consensus misses on Revuforj and Niktimvo sales…
Syndax price target lowered to $37 from $40 at Jefferies
Jefferies lowered the firm’s price target on Syndax (SNDX) to $37 from $40 and keeps a Buy rating on the shares following Q1 results. The firm noted that the revuforj…
Syndax price target raised to $37 from $35 at Barclays
Barclays raised the firm’s price target on Syndax (SNDX) to $37 from $35 and keeps an Overweight rating on the shares. The firm updated the company’s model post the Q1…
Syndax Pharmaceuticals Earnings Call Transcript: Q1 2026
Q1 2026 revenue surged 224% year-over-year to $64.9 million, driven by strong Revuforj and Niktimvo sales. Revuforj saw robust adoption in both NPM1 and KMT2A, while Niktimvo maintained solid growth and persistency. Multiple pivotal trial readouts and label expansion opportunities are expected in 2026.
Syndax Reports First Quarter 2026 Financial Results and Provides Business Update
– Total revenue of $64.9 million in 1Q26, a 224% year-over-year increase – – Revuforj ® (revumenib) net revenue of $48.9 million in 1Q26, highlighting leadership in menin inhibition and increasing upt...
Syndax to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on April 30, 2026
NEW YORK, April 24, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will rep...
Syndax price target raised to $34 from $28 at Goldman Sachs
Goldman Sachs analyst Corinne Johnson raised the firm’s price target on Syndax (SNDX) to $34 from $28 and keeps a Buy rating on the shares. Ahead of Syndax’s Phase 2…
Syndax price target lowered to $43 from $45 at Mizuho
Mizuho lowered the firm’s price target on Syndax (SNDX) to $43 from $45 and keeps an Outperform rating on the shares. The firm updated models in the small-cap biotech space…
Syndax assumed with a Buy at Jefferies
Jefferies assumed coverage of Syndax (SNDX) with a Buy rating and a price target of $40, down from $48. Revuforj is winning today and the competition from Kura Oncology (KURA)…
Syndax Pharmaceuticals Transcript: Barclays 28th Annual Global Healthcare Conference
Two leading oncology products are driving strong sales and market adoption, with Revuforj becoming standard of care in acute leukemia and Niktimvo expanding in chronic GVHD. Combination strategies, robust clinical development, and disciplined financial management support continued growth, while new indications and collaborations are advancing the pipeline.
Syndax Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026
Strong commercial launches for two products are driving revenue growth and market expansion, with pivotal studies underway to enter the frontline AML market and new indications like myelofibrosis and IPF. Physician education and scientific engagement remain priorities, while profitability is expected soon due to robust sales and controlled expenses.
Syndax price target raised to $45 from $33 at JPMorgan
JPMorgan raised the firm’s price target on Syndax (SNDX) to $45 from $33 and keeps an Overweight rating on the shares. The Phase 2 MAXPIRe data for Niktimvo in idiopathic…
Syndax Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference
Two commercial products have set new sales benchmarks in AML and chronic GVHD, with strong market penetration and expanding indications. The company is well-funded, expects to reach profitability, and is advancing pivotal trials in AML and IPF, with major data readouts anticipated in 2026.
Syndax price target raised to $57 from $51 at Citi
Citi raised the firm’s price target on Syndax (SNDX) to $57 from $51 and keeps a Buy rating on the shares.
Syndax reports Q4 EPS (78c), consensus (58c)
Reports Q4 revenue $68.73M, consensus $64.75M. As of December 31, 2025, Syndax (SNDX) had cash, cash equivalents, and short-term investments of $394.1M and 87.7M common shares and prefunded warrants o...
Syndax Pharmaceuticals Earnings Call Transcript: Q4 2025
2025 revenue reached $172.4M, driven by strong launches of Revuforj and Niktimvo, both exceeding benchmarks. Revuforj expanded into NPM1 AML, while Niktimvo captured 20% of the third-line-plus GVHD market. Robust pipeline and financial position support continued growth.
Syndax Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
– Total revenue of $68.7 million in 4Q25 and $172.4 million in FY2025 – – Revuforj ® (revumenib) net revenue of $44.2 million in 4Q25, a 38% increase vs 3Q25, and $124.8 million in FY2025 – – Niktimv...
Syndax Announces Participation in March Investor Conferences
NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. M...
Syndax to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call and Webcast on February 26, 2026
NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will repo...
Syndax Pharmaceuticals Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026
Strong revenue growth and expanding indications for both lead products are driving momentum, with maintenance therapy uptake rising and new clinical milestones expected in 2026. Strategic partnerships and disciplined spending support a clear path to profitability.
Syndax Announces Participation at the 2026 Guggenheim Emerging Outlook: Biotech Summit
NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. M...